An FDA advisory committee is set to meet this week to discuss a drug developed by Biogen and Ionis to treat a rare form of Lou Gehrig's disease.
It appears likely that a new drug to treat amyotrophic lateral sclerosis will get approval in the U.S. Regulators shared their thinking ahead of an advisory committee meeting.
The Food and Drug Administration committee is scheduled to meet Wednesday to discuss Biogen Inc. BIIB and Ionis Pharmaceuticals Inc.’s IONS tofersen as a treatment for a rare type of ALS that is associated with the superoxide dismutase 1 gene. Wall Street analysts largely view the approval of tofersen as likely. However, most analysts say they don’t expect this drug to drive the kind of impact they’re looking for on Biogen’s business. Instead, all eyes remain on lecanemab, Biogen and Eisai’s 4523 treatment for Alzheimer’s disease, which received accelerated approval in January.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Wall Street strengthens after big bank deal, regulator movesNEW YORK (AP) — Most of Wall Street is rising Monday after regulators pushed together two huge banks over the weekend and made other moves to build confidence in the struggling industry. The S&P 500 was 0.5% higher in morning trading.
Baca lebih lajut »
Dow jumps 350 points after bank deals calm Wall Street jittersTraders have raised bets of the Fed likely hitting a pause on rate hikes on Wednesday to ensure financial stability.
Baca lebih lajut »
Global banking turbulence prompts Wall Street banks to trim hawkish Fed betsGoldman Sachs is expecting a pause this week from the U.S. Federal Reserve after a year-long rate increase campaign as Wall Street banks scale back their hawkish expectations in the aftermath of the ongoing global banking turmoil.
Baca lebih lajut »
Asia-Pacific markets to rise after Wall Street sees gains on optimism led by regional banksAsian markets trade higher as banks rally on the hopes that troubles in the U.S. and Europe are averted.
Baca lebih lajut »
How middle managers on Wall Street go wrongInsider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Baca lebih lajut »
First Republic Bank woes mount despite Wall Street rescueShares of First Republic Bank continued their free-fall despite a rare move by the biggest U.S. banks to pump $30 billion into the regional lender.
Baca lebih lajut »